The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-05 and is reviewed periodically as new material appears.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
== History == Seer was founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, based on nanoparticle technologies developed in Farokhzad’s laboratory at Brigham and Women’s Hospital, Harvard Medical School. Early investors included Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity. In September 2020, Seer spun off PrognomiQ to focus on clinical applications, such as developing a liquid biopsy blood test for early lung cancer detection. Philip Ma became President and CEO of PrognomiQ. Farokhzad serves as chair of the board of directors of PrognomiQ. Seer retains approximately 19% ownership in the company. On December 4, 2020, Seer completed its initial public offering, raising approximately $336.2 million in proceeds. Underwriters included J.P. Morgan, Morgan Stanley, Bank of America Securities, and Cowen. Seer launched the Proteograph Product Suite in January 2021, which included the SP100 automation instrument and the Proteograph RISE assay kit. In June 2023, the company introduced the Proteograph XT assay kit, which increased system throughput by 150%. In May 2025, Seer released a high-throughput version of the Proteograph Product Suite, including the Proteograph ONE Assay and SP200 Automation Instrument. The system supports processing of up to 1,000 samples per week and is designed for large-scale proteomic studies.
=== Tetrahedron legacy === When visiting the Tetra Pak factory in Lund in the 1950s, Danish physics professor and Nobel Prize laureate Niels Bohr allegedly claimed to "never have seen such an adequate practical application of a mathematical problem" as the tetrahedron package and the innovation of the milk tetrahedron. The question of who invented it has been the subject of some disagreements. Erik Wallenberg did not receive any formal recognition until 1991, when he was awarded the Royal Swedish Academy of Engineering Sciences' Great Gold Medal for outstanding achievement for the invention.
Freezer burn is a condition that occurs when frozen food has been damaged by dehydration and oxidation due to air reaching the food. It is generally caused by food not being securely wrapped in air-tight packaging. Freezer burn appears as grayish-brown leathery spots on frozen food and occurs when air reaches the food's surface and dries the product. Color changes result from chemical changes in the food's pigment. Freezer burn does not make the food unsafe; it merely causes dry spots in foods. The food remains usable and edible, but removing the freezer burns can improve the flavor. The dehydration of freezer-burned food is caused by water sublimating from the food into the surrounding atmosphere. The lost water may then be deposited elsewhere in the food and packaging as snow-like crystals. Fluctuation of temperatures in a freezer, such that the temperature does not remain consistently below −18 °C, can also speed up freezer burn.
The medal for the Nobel Prize in Physiology or Medicine is given by the Nobel Assembly at the Karolinska Institute. The reverse of the medal depicts the 'Genius of Medicine holding an open book in her lap, collecting the water pouring out from a rock in order to quench a sick girl's thirst'. It is inscribed "Inventas vitam iuvat excoluisse per artes" ("It is beneficial to have improved (human) life through discovered arts") an adaptation of "inventas aut qui vitam excoluere per artes" from line 663 from book 6 of the Aeneid by the Roman poet Virgil. A plate below the figures is inscribed with the name of the recipient. The text "REG. UNIVERSITAS MED. CHIR. CAROL." denoting the Karolinska Institute is also inscribed on the reverse. It was designed by Erik Lindberg and is manufactured by Svenska Medalj in Eskilstuna.
== Guest appearances == Several celebrities or future celebrities made uncredited appearances, either as part of the main storyline or in brief segments; among these were Richard Sanders who later gained fame playing Les Nessman on WKRP in Cincinnati. Ordinary citizens were interviewed by the kids in selected segments of some episodes in a "man on the street" format.
Sources: en.wikipedia.org
greater flexibility of meal times, carbohydrate quantities, and physical activities, and better glycemic control to reduce the incidence and severity of the complications of diabetes. Major disadvantages of intensive/flexible therapy are that it requires greater amounts of education and effort to achieve the goals, and it increases the daily cost for glucose monitoring four or more times a day. This cost can substantially increase when the therapy is implemented with an insulin pump and/or continuous glucose monitor. It is a common notion that more frequent hypoglycemia is a disadvantage of intensive/flexible regimens. The frequency of hypoglycemia increases with increasing effort to achieve normal blood glucoses with most insulin regimens, but hypoglycemia can be minimized with appropriate glucose targets and control strategies. The difficulties lie in remembering to test, estimating meal size, taking the meal bolus and eating within the prescribed time, and being aware of snacks and meals that are not the expected size. When implemented correctly, flexible regimens offer greater ability to achieve good glycemic control with easier accommodation to variations of eating and physical activity. A 2020 Cochrane systematic review did not find enough evidence of reduction of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke when comparing insulin to metformin monotherapy.
This end proves to be both more thermodynamically favored for the addition of G-actin and kinetically dynamic as well. Simultaneously, older G-actin monomers "fall off" of the pointed end of the microfilament. At the "pointed end" of the F-actin polymer, actin monomers are bound to ADP, which dissociates more readily and rapidly than ATP-bound actin, which is found at the "barbed end" of the polymer. Thus, in environments with high concentrations of free actin subunits, filamentous growth at the "barbed end" remains greater than that of the "pointed end". This "tread-milling", essentially exists as a simplified explanation of the actin remodeling process.
== Interactions == Also like cyclosporin, it has a wide range of interactions. Tacrolimus is primarily metabolised by the cytochrome P450 system of liver enzymes, and there are many substances that interact with this system and induce or inhibit the system's metabolic activity. Interactions include that with grapefruit which increases tacrolimus plasma concentrations. As infections are a major cause of morbidity and mortality in the post-transplant patient, the most commonly reported interactions include interactions with anti-microbial drugs. Macrolide antibiotics including erythromycin and clarithromycin, as well as several of the newer classes of antifungals, especially of the azole class (fluconazole, voriconazole), increase tacrolimus levels by competing for cytochrome enzymes.
The first Pretzel Time store opened in Trumbull, Connecticut. The company was originally incorporated as Mr. Pretzel Inc. in 1991, but quickly changed its name to Pretzel Time by the time it became a popularly franchised mall-based store in the Northeast. In 1999, Mrs. Fields Famous Brands purchased Pretzelmaker. Later it sold the brands to NexCen in 2007 in a combined transaction total of $29.7 million. In 1996, Mrs. Fields had acquired the now-defunct Hot Sam which it merged with Pretzelmaker in 2005. Global Franchise Group (GFG) purchased NexCen Franchise Management in 2010, and merged Pretzel Time and Pretzelmaker into one brand as Pretzelmaker. Pretzelmaker today is the second largest retailer of freshly baked, hand rolled and twisted pretzels. On June 28, 2021, Global Franchise Group announced that it would be acquired by FAT Brands, owners of Fatburger and Johnny Rockets. The acquisition was completed on July 22. On January 26, 2026, parent company FAT Brands filed for Chapter 11 bankruptcy protection in an effort to shed billions of dollars in debt. The company listed assets and liabilities between $1 billion and $10 billion. After receiving court approval for the sale of its assets, FBG Bid Co. officially acquired the remaining assets from FAT Brands for $595 million on June 18, 2026, including Pretzelmaker.
Sources: en.wikipedia.org
=== Further investigations and arrests === Following the verdict, police continued to investigate whether Letby had harmed other infants. Detectives reviewed around 30 cases at the Countess of Chester Hospital that had been identified as "suspicious". Neonatologists examined approximately 4,000 admissions at that hospital, where Letby had worked from 2012, and at Liverpool Women's Hospital, where she had completed two placements in 2012 and 2015, and were asked to refer any "unexpected and unexplained" deteriorations to police. At least one family was informed that their child's case at Liverpool Women's Hospital formed part of the inquiry. Cheshire Police interviewed Letby under caution in relation to deaths at both hospitals. On 2 July 2025, the Crown Prosecution Service confirmed that it was considering further charges based on new evidence provided by the police. On 20 January 2026, after reviewing evidence relating to allegations of murder involving two children and attempted murder involving seven others, the Crown Prosecution Service announced that no further charges would be brought against Letby. On 4 October 2023, Cheshire Constabulary announced an investigation into potential corporate manslaughter at the Countess of Chester Hospital. On 1 July 2025, three members of the hospital's former senior leadership team were arrested on suspicion of gross negligence manslaughter. On 22 April 2026 one of the three was arrested and bailed for perverting the course of justice.
Glypromate (Gly-Pro-Glu, GPE) is a tripeptide fragment derived from the N-terminus of the endogenous growth factor IGF-1. It has antiinflammatory and neuroprotective effects and is of interest in the treatment of neurological conditions such as Alzheimer's disease and Parkinson's disease. The simple GPE peptide has poor blood-brain barrier penetration and is rapidly metabolised in the body, however a number of synthetic derivatives of GPE have been developed with improved properties.
Crystalline silica, National Institute for Occupational Safety and Health, US. Preventing Silicosis and Deaths in Construction workers, National Institute for Occupational Safety and Health, US. OSHA’s Respirable Crystalline Silica Standard for Construction, Occupational Safety and Health Administration, US. CDPH's Engineered Stone (ES) Silicosis Surveillance Dashboard, California Department of Public Health Occupational Health Branch
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.